Metformin Fights Vascular Aging Beyond Blood Sugar Control

Cardiovascular disease driven by vascular aging remains a leading cause of mortality worldwide, and finding interventions that slow arterial deterioration is a central goal of longevity medicine. Metformin, a decades-old biguanide diabetes drug, is now being reexamined as a potential geroprotector with effects that extend far beyond glucose regulation.

This 2025 narrative review, published in Drugs & Aging, systematically examines the mechanisms by which metformin may counteract vascular aging. The authors draw on a broad spectrum of clinical trials, epidemiological data, and preclinical models to build a mechanistic and translational case for metformin's cardiovascular benefits.

At the molecular level, metformin's activation of AMPK (AMP-activated protein kinase) is identified as a central driver of its anti-aging effects, reducing metabolic dysregulation and slowing cellular senescence in vascular tissue. The drug also attenuates oxidative stress, helping preserve endothelial function—a key early marker of arterial health. Its anti-inflammatory and lipid-lowering properties further reduce arterial rigidity and slow the formation of atherosclerotic plaques.

Clinical and preclinical studies cited in the review confirm improvements in endothelial function, reductions in arterial stiffness, and lower rates of cardiovascular events in metformin users. These findings collectively position metformin as a candidate geroprotector suitable for individuals at risk of age-related vascular decline, not just those with diabetes.

The authors acknowledge that while the evidence base is encouraging, critical gaps remain. Optimal dosing for vascular aging (as distinct from glycemic control), the full spectrum of long-term biological effects, and rigorous longitudinal outcome data are still lacking. Well-designed follow-up studies are called for before metformin can be broadly adopted as a vascular aging intervention.